^
    2ms
    MERTK Inhibitor Associated Retinal Toxicity in a Human. (PubMed, Retin Cases Brief Rep)
    Patients taking MERTK inhibitors should be monitored by an ophthalmologist while on the drug. If toxicity develops, discussion of whether to continue the medication should take place between the patient, ophthalmologist, and oncologist, with consideration of the risks of vision loss versus benefits of taking the medication from a cancer perspective.
    Journal
    |
    MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    PF-07265807
    8ms
    Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Pfizer | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
    over1year
    Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=161 --> 61
    Enrollment closed • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
    2years
    Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=161, Recruiting, Pfizer | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
    3years
    Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=155, Recruiting, Pfizer | N=37 --> 155 | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807